Semaglutide — Drug Intelligence | 79 EU Trials

Filter these 79 trials by condition, phase, country and more.

Open in Search →

79 Registered trials

31 Recruiting

31 Completed trials

44 Sponsors

24 Countries

Phase III

Phase II

Phase IV

Phase III: 21 Phase II/III: 1 Phase II: 24 Phase III/IV: 4 Phase IV: 27 Phase I (Other): 1 Other: 1

Oversight events:

8 serious breaches 1 temporary halt across 6 trials

View oversight register →

Indications tested

Obesity 10 Type 2 diabetes mellitus 5 Non-alcoholic steatohepatitis 3 Chronic kidney disease 3 Overweight 3 Diabetes mellitus 2 Coronary artery disease 1 Acute coronary syndrome 1 Multiple sclerosis 1 Palpitations 1 Atrial fibrillation 1 Craniopharyngioma 1

Sponsors using this IMP

Novo Nordisk A/S 19 Region Hovedstaden 5 Rigshospitalet 5 Region Midtjylland 3 Steno Diabetes Center Copenhagen 3 Aarhus University Hospital 2 Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca 2 Karolinska University Hospital 2 Odense University Hospital 2 University College Dublin 2 UZ Leuven 2 AstraZeneca AB 1

All trials

79 total

Safety and efficacy of oral semaglutide in hyperglycaemic patients after renal transplantation Not authorised

2023-504159-29-00 Phase II 1 country Rigshospitalet
Short title: TOTT: Tailoring Obesity Treatment Trial Not authorised

2024-510802-10-00 Phase II/III 1 country Esbjerg Sygehus
Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the t… Not authorised

2025-523374-17-01 Phase IV 1 country Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
The effect of semaglutide therapy on hepatic fat content and on the acute response of liver fat to high-fat load Pending

2023-504988-16-00 Phase III 1 country Institut Klinicke A Experimentalni Mediciny
A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending

2023-509176-42-00 Phase III/IV 14 countries Novo Nordisk A/S
SEMAFORCRANIO : Multicenter, double-blind, parallel, randomized controlled trial of the efficacy of semaglutide in hypothalamic obesity seco… Pending

2024-511114-20-00 Phase III 1 country Centre Hospitalier Universitaire D'Angers
Weight management with orismilast alone or in combination with s.c. semaglutide (WELOSITI) Pending

2024-517463-23-00 Phase II 1 country Gentofte Hospital
Effects of GLP-1 analogue in multiple sclerosis Pending

2024-519235-42-00 Phase II 1 country Comenius University Bratislava
Impact of GLP1-RAs on inflammation and endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 trial. Pending

2025-520802-37-00 Phase IV 1 country Universita' Degli Studi Di Napoli Federico II
Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascu… Pending

2025-522486-29-01 Phase III 1 country Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pas…
Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the t… Pending

2025-523374-17-03 Phase IV 1 country Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
ARMYDA - 10 study Pending

2025-523977-40-00 Phase IV 1 country Azienda Ospedaliero-Universitaria Maggiore Della Carita
Waiting on Atrial fibrillation Intervention Therapy (WAIT) Study Pending

2025-524182-25-00 Phase IV 1 country Karolinska University Hospital
Effect on the tolerability of semaglutide in overweight adults without diabetes Pending

2025-524612-11-00 Phase IV 1 country University Of Tartu
Healing Diabetic Foot Ulcers with Semaglutide Pending

2025-524738-24-00 Phase IV 1 country Radboud universitair medisch centrum Stichting
TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study) Pending

2025-524819-37-00 Phase IV 1 country Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating… Pending

2026-526016-36-00 Phase IV 1 country UZ Leuven
Obesity and Semaglutide in Type 1 Diabetes Therapy (OBES1TY): A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-In… Recruiting

2025-522326-13-00 Phase III 1 country Region Hovedstaden
AMAZE 8: A research study investigating how well the medicine NNC0487-0111 compared to semaglutide helps people with excess body weight and … Recruiting

2024-520446-31-00 Phase III 7 countries Novo Nordisk A/S
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone… Recruiting

2024-513416-98-00 Phase II 2 countries Karolinska University Hospital
Efficacy and Safety of KAI-9531 compared with Semaglutide in Participants Living With Obesity Who Do Not Have Diabetes Recruiting

2025-523511-11-00 Phase III 2 countries Kailera Therapeutics Inc.
An open-label, single-center, non-controlled pilot clinical trial to assess the efficacy of weekly semaglutide in combination with regular c… Recruiting

2025-524177-16-00 Phase II 1 country Institute Of Tropical Medicine
A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder Recruiting

2025-524163-21-00 Phase II 1 country Region Hovedstaden
A research study comparing how well different doses of the medicine NNC0662-0419 lower blood sugar in people with type 2 diabetes Recruiting

2025-523260-20-00 Phase II 6 countries Novo Nordisk A/S

Showing 1–24 of 79 trials

← All drugs A–Z